2. Search Result
Search Result
Results for "

Cancer vaccine

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

4

Screening Libraries

2

Fluorescent Dyes

8

Biochemical Assay Reagents

11

Peptides

1

Inhibitory Antibodies

1

Natural
Products

10

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-107202
    Polyinosinic-polycytidylic acid
    60+ Cited Publications

    Poly(I:C)

    		 RIG-I-like receptor (RLR) Toll-like Receptor (TLR) PKD HSP Bcl-2 Family Interleukin Related Apoptosis Infection Inflammation/Immunology Cancer
    Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis .
    Polyinosinic-polycytidylic acid
  • HY-135748
    Polyinosinic-polycytidylic acid sodium
    Maximum Cited Publications
    62 Publications Verification

    Poly(I:C) sodium

    		 RIG-I-like receptor (RLR) Toll-like Receptor (TLR) Apoptosis Inflammation/Immunology Cancer
    Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis .
    Polyinosinic-polycytidylic acid sodium
  • HY-16724
    Indoximod
    10+ Cited Publications

    1-Methyl-D-tryptophan; NLG-8189

    		 Indoleamine 2,3-Dioxygenase (IDO) Cancer
    Indoximod (1-Methyl-D-tryptophan) is an orally active indoleamine 2,3-dioxygenase (IDO) pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR. Indoximod is an immunometabolic adjuvant used for the research of cancer .
    Indoximod
  • HY-150218
    Agatolimod sodium
    1 Publications Verification

    ODN 2006 sodium; ODN 7909 sodium; PF-3512676 sodium; CpG 7909 sodium

    		 Toll-like Receptor (TLR) Cancer
    Agatolimod sodium (ODN 2006) is a class B CpG ODN and is a TLR9 agonist. Agatolimod sodium can be used as vaccine adjuvant. Agatolimod sodium can be used for the research of cancer. Sequence: 5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’ .
    Agatolimod sodium
  • HY-Y1883
    Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant
    20+ Cited Publications

    		 Environmental Pollutants Biochemical Assay Reagents Apoptosis Infection Cancer
    Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is a non-denaturing detergent that solubilizes lipid membranes. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is commonly used in laboratories and is applied to vaccines at different stages of the manufacturing process. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is listed as an excipient in certain vaccines including split virus influenza vaccines. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is a nonionic surfactant. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant induces Apoptosis in prostate and colon cancer cell lines and reduces the infectivity of classic enveloped viruses such as WNV .
    Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant
  • HY-148068
    STING agonist-20

    		STING Inflammation/Immunology Cancer
    STING agonist-20 (compound 95) is a potent STING agonist used in the synthesis of XMT-2056. STING agonist-20 can be used as a vaccine adjuvant in the study of cancer and other inflammatory, immune diseases .
    STING agonist-20
  • HY-Y1883A
    Polyethylene glycol mono(4-tert-octylphenyl) ether
    20+ Cited Publications

    		 Environmental Pollutants Biochemical Assay Reagents Infection Cancer
    Polyethylene glycol mono(4-tert-octylphenyl) ether is a non-denaturing detergent that solubilizes lipid membranes. Polyethylene glycol mono(4-tert-octylphenyl) ether is commonly used in laboratories and is applied to vaccines at different stages of the manufacturing process. Polyethylene glycol mono(4-tert-octylphenyl) ether is listed as an excipient in certain vaccines including split virus influenza vaccines. Polyethylene glycol mono(4-tert-octylphenyl) ether is a nonionic surfactant. Polyethylene glycol mono(4-tert-octylphenyl) ether induces Apoptosis in prostate and colon cancer cell lines and reduces the infectivity of classic enveloped viruses such as WNV .
    Polyethylene glycol mono(4-tert-octylphenyl) ether
  • HY-150741
    ODN 2216
    1 Publications Verification

    		 Toll-like Receptor (TLR) IFNAR Interleukin Related Infection Inflammation/Immunology Cancer
    ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
    ODN 2216
  • HY-104004
    Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH

    Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH; Fmoc-Ser[GalNAc(Ac)3-α-D]-OH; Fmoc-Ser(Ac3AcNH-α-Gal)-OH

    		 Amino Acid Derivatives Drug Intermediate Cancer
    Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH (Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH) is a protected glycosylated amino acid and Tn antigen. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH serves as a building block in the solid-phase synthesis of Tn-based cancer vaccine constructs. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH supports solid-phase peptide synthesis .
    Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH
  • HY-150750
    ODN M362

    		Toll-like Receptor (TLR) Apoptosis Inflammation/Immunology Cancer
    ODN M362, a class C oligodeoxynucleotide, is a TLR-9 agonist and can be used as a vaccine adjuvant. ODN M362 induces cancer cell apoptosis .
    ODN M362
  • HY-150741C
    ODN 2216 sodium
    1 Publications Verification

    		 Toll-like Receptor (TLR) Cancer
    ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .
    ODN 2216 sodium
  • HY-P11303
    PADRE peptide

    		CD74 MHC Neurological Disease Cancer
    PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4 + T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8 + T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer .
    PADRE peptide
  • HY-N4087
    Platycodin D2
    3 Publications Verification

    		 Mitophagy Autophagy Ferroptosis Interleukin Related IFNAR Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Platycodin D2 is an orally active triterpenoid saponin found in Platycodon grandiflorum. Platycodin D2 induces mitophagy in cancer cells through NIX, thereby activating the P21/CyclinA2 pathway and promoting cell senescence. Platycodin D2 induces mitochondrial dysfunction, enhances autophagy, inhibits hepatocellular carcinoma cell proliferation, and exhibits anti-tumor activity against multiple cancer cell types. Platycodin D2 promotes mRNA expression of T-bet, GATA-3, Th1 cytokines IL-2 and IFN-γ, and Th2 cytokines IL-4 and IL-10, enhances splenocyte proliferation, and acts as a vaccine adjuvant with low rabbit red blood cell hemolytic activity. Platycodin D2 induces mitochondrial ROS production, incomplete autophagy, and ferroptosis to inhibit breast cancer cell proliferation. Platycodin D2 can be used for the research of cancer, inflammation and immunology .
    Platycodin D2
  • HY-107202A
    Poly (I:C):Kanamycin (1:1)
    5+ Cited Publications

    		 Toll-like Receptor (TLR) RIG-I-like receptor (RLR) PKD HSP Bcl-2 Family Interleukin Related Apoptosis Infection Inflammation/Immunology Cancer
    Poly(I:C):Kanamycin (1:1) is a mixture of Poly(I:C) (HY-107202) and Kanamycin (HY-16566). Poly(I:C) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Poly(I:C) can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Poly(I:C) can directly trigger cancer cells to undergo apoptosis. Kanamycin stabilizes Poly(I:C) .
    Poly (I:C):Kanamycin (1:1)
  • HY-P11058
    OVA(250-264)

    OVAp

    		 MHC Cancer
    OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8 + T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research .
    OVA(250-264)
  • HY-134958
    Polyinosinic-polycytidylic acid potassium

    Poly(I:C) potassium

    		 Toll-like Receptor (TLR) Apoptosis Inflammation/Immunology Cancer
    Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid potassium can directly trigger cancer cells to undergoApoptosis .
    Polyinosinic-polycytidylic acid potassium
  • HY-150750A
    ODN M362 sodium

    		Toll-like Receptor (TLR) Apoptosis Interleukin Related TNF Receptor IFNAR Inflammation/Immunology Cancer
    ODN M362 sodium is a TLR9 agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of TLR9/TLR6, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer .
    ODN M362 sodium
  • HY-145973A
    3'OMe-m7GpppAmpG ammonium solution (100 mM)

    m7(3'OMeG)(5')ppp(5')(2'OMeA)pG ammonium solution (100 mM)

    		 DNA/RNA Synthesis Others
    3'OMe-m7GpppAmpG (m7(3'OMeG)(5')ppp(5')(2'OMeA)pG) ammonium solution (100 mM) is a trinucleotide Cap analogue. 3'OMe-m7GpppAmpG ammonium shows a significant translational efficiency. 3'OMe-m7GpppAmpG ammonium can be used as a potential molecular biology tool in the field of mRNA vaccines and mRNA transfection, such as protein production, gene therapy and anti-cancer immunization .
    3'OMe-m7GpppAmpG ammonium solution (100 mM)
  • HY-107202GL
    Polyinosinic-polycytidylic acid (GMP Like)

    Poly(I:C) (GMP Like)

    		 Toll-like Receptor (TLR) PKD HSP Bcl-2 Family Interleukin Related Apoptosis Infection Inflammation/Immunology Cancer
    Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis .
    Polyinosinic-polycytidylic acid (GMP Like)
  • HY-172526
    4A3-SCC-10

    		Liposome Cancer
    4A3-SCC-10 is a biodegradable ionizable lipid containing disulfide bonds. 4A3-SCC-10 can be used to prepare lipid nanoparticles (LNPs) for the delivery of mRNA in vitro and in vivo. 4A3-SCC-10 can be used for broad applications such as gene editing, vaccine, and cancer detection .
    4A3-SCC-10
  • HY-P11060
    MC38 SLP Adpgk

    Adpgk peptide

    		 MHC Cancer
    MC38 SLP Adpgk (Adpgk peptide) is an H-2 K b-restricted colorectal cancer neoantigen peptide. MC38 SLP Adpgk is formulated into PCNP nanocomplexes together with CpG ODN. PCNP vaccines significantly enhance the co-delivery efficiency of neoantigens and adjuvants to lymphoid organs, and activate cytotoxic T cells. PCNP vaccines not only protect mice from MC-38 colorectal tumor invasion, but also exhibit anti-tumor efficacy in established colorectal tumor models and significantly prolong the survival of tumor-bearing mice .
    MC38 SLP Adpgk
  • HY-135748A
    Poly (I:C):Kanamycin (1:1) sodium
    55+ Cited Publications

    		 RIG-I-like receptor (RLR) Toll-like Receptor (TLR) Apoptosis Infection Cancer
    Poly (I:C):Kanamycin (1:1) sodium is an isometric complex of Poly (I:C) (HY-135748) and Kanamycin (HY-16566). Poly(I:C) sodium, a synthetic analog of double-stranded RNA, is a TLR3 and retinoic acid-inducible gene I receptor (RIG-I and b>MDA5) agonist. Poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses and induce apoptosis in cancer cells . Kanamycin is an orally active antibacterial agent (Gram-negative/positive bacteria) that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit. Kanamycin shows good inhibitory activity against Mycobacterium tuberculosis (susceptible and drug-resistant) and Klebsiella pneumoniae, and can be used in the research of tuberculosis and pneumonia .
    Poly (I:C):Kanamycin (1:1) sodium
  • HY-106204
    Nelipepimut-S

    		EGFR Cancer
    Nelipepimut-S is a peptide vaccine which targets HER2. Nelipepimut-S has immune activity against HER2 positive breast cancer .
    Nelipepimut-S
  • HY-P10701
    Q11 peptide

    		Biochemical Assay Reagents Inflammation/Immunology Cancer
    Q11 peptide is a β-sheet-forming peptide that plays an important role in self-assembly and targeted applications. As a scaffold peptide, Q11 peptide can display immunogenic epitopes and is widely used in peptide-based immune vaccine research. Additionally, Q11 peptide can be conjugated with MUC1 glycopeptides for the study of self-assembling, adjuvant-free MUC1 glycopeptide vaccines. Q11 peptide holds great potential for research in the field of cancer immunology .
    Q11 peptide
  • HY-145973
    3'OMe-m7GpppAmpG

    m7(3'OMeG)(5')ppp(5')(2'OMeA)pG

    		 DNA/RNA Synthesis Others
    3'OMe-m7GpppAmpG is a trinucleotide Cap analogue. 3'OMe-m7GpppAmpG shows a significant translational efficiency. 3'OMe-m7GpppAmpG can be used as a potential molecular biology tool in the field of mRNA vaccines and mRNA transfection, such as protein production, gene therapy and anti-cancer immunization .
    3'OMe-m7GpppAmpG
  • HY-151512
    A12-Iso5-4DC19

    		Liposome Inflammation/Immunology Cancer
    A12-Iso5-4DC19 is an ionizable cationic lipid. A12-Iso5-4DC19 can facilitate mRNA delivery and be used for the research of RNA vaccines .
    A12-Iso5-4DC19
  • HY-149664
    3β-[N-(N′,N′-Dimethylaminoethyl)carbamoyl]cholesterol

    DC-Chol

    		 Liposome Cancer
    3β-[N-(N′,N′-Dimethylaminoethyl)carbamoyl]cholesterol, a lipid, has been investigated in cancer gene therapy and vaccine delivery system .
    3β-[N-(N′,N′-Dimethylaminoethyl)carbamoyl]cholesterol
  • HY-P10686
    CH401 peptide

    		EGFR Cancer
    CH401 peptide is a HER2-derived antigen peptide. After being bound to the artificial viral capsid by a self-assembled β-cyclic peptide, CH401 peptide is encapsulated in a lipid bilayer containing the lipid adjuvant α-GalCer, and can be studied as a self-adjuvant anti-breast cancer vaccine candidate .
    CH401 peptide
  • HY-164395
    Sipuleucel-T

    		Phosphatase Inflammation/Immunology Cancer
    Sipuleucel-T is a cancer vaccine. Sipuleucel-T recognizes prostatic acid phosphatase (PAP), present PAP antigens, and stimulates the immune response against prostate cancer cells .
    Sipuleucel-T
  • HY-W440893
    DSPE-PEG5000-OH

    		Biochemical Assay Reagents Others
    DSPE-PEG5000-OH is a linear phospholipid PEG polymer. The lipid tails allow encapsulation of hdyrophobic therapeutics while the PEG chain maintains its hydrophilicity. The polymer can be used for drug nanocarrier, such as liposomal anti cancer drug or mRNA/DNA vaccine.
    DSPE-PEG5000-OH
  • HY-W441003
    DSPE-PEG2000-IA

    		Biochemical Assay Reagents Others
    DSPE-PEG2000-IA is a thiol reactive phospholipid polyPEG. The iodoacetyll group is reactive with thiol to produce a thioether linkage. The polymer can self-assemble in water to form lipid bilayer and can be used to encapsulate drugs in targeted delivery application, such as liposomal doxorubicin as an anti cancer drug or mRNA vaccine.
    DSPE-PEG2000-IA
  • HY-162726
    GCS-11

    		Interleukin Related Cancer
    GCS-11 is a powerful natural killer T (NKT) cell agonist. It boosts the production of IFN-γ and IL-4, with a particular selectivity for IFN-γ. GCS-11 exhibits anticancer activity. GCS-11 has the potential for research into cancer immunotherapies or vaccine development as a promising adjuvant .
    GCS-11
  • HY-16724R
    Indoximod (Standard)

    1-Methyl-D-tryptophan (Standard); NLG-8189 (Standard)

    		 Indoleamine 2,3-Dioxygenase (IDO) Reference Standards Cancer
    Indoximod (Standard) is the analytical standard of Indoximod. This product is intended for research and analytical applications. Indoximod (1-Methyl-D-tryptophan) is an orally active indoleamine 2,3-dioxygenase (IDO) pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR. Indoximod is an immunometabolic adjuvant used for the research of cancer .
    Indoximod (Standard)
  • HY-156087G
    Cholicamideβ (GMP)

    		Apoptosis Necroptosis Cancer
    Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis .
    Cholicamideβ (GMP)
  • HY-156087
    Cholicamideβ

    		Apoptosis Necroptosis Cancer
    Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis .
    Cholicamideβ
  • HY-P10295
    p53 (232-240)

    		MDM-2/p53 Cancer
    p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .
    p53 (232-240)
  • HY-162116
    TLR7 agonist 18

    		Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    TLR7 agonist 18 (Compound 21a) is a selective Toll-like receptor 7 (TLR7) agonist with an EC50 of 7.8 μM. TLR7 agonist 18 is not cytotoxic to hTLR7 cotransfected HEK293 cell lines and can induce the secretion of several cytokines, including IL-1β, IL-12p70, IL-8, and TNF-α. TLR7 agonist 18 can be used in vaccine, asthma, allergy and anti-cancer research .
    TLR7 agonist 18
  • HY-183596
    L-His-BPA

    		Drug Intermediate Cancer
    L-His-BPA is a prodrug of L-p-Boronophenylalanine (L-BPA) (HY-W087830), formed by the peptide bond linkage of L-histidine (L-His) (HY-N0832) and L-BPA. L-His-BPA is rapidly cleaved by endogenous proteases to de novo release L-BPA in the systemic circulation. When used in combination with neutron irradiation, L-His-BPA induces complete and durable tumor regression, elicits cancer vaccine responses, and produces abscopal inhibitory effects on unirradiated distant tumors. L-His-BPA can be used in studies of boron neutron capture therapy (BNCT) for relapsed/advanced solid tumors .
    L-His-BPA
  • HY-183597
    L-BPA-BPA

    		Drug Derivative Cancer
    L-BPA-BPA is an aromatic dipeptide and an analog of L-BPA (HY-W087830). L-BPA-BPA undergoes rapid hydrolytic cleavage in vivo to release the boron neutron capture agent L-BPA. L-BPA-BPA enables boron delivery to tumors; when used in combination with neutron irradiation, it also induces immunological effects including vaccine responses and abscopal tumor suppression. L-BPA-BPA can be used in the research of colon cancer and hypopharyngeal cancer .
    L-BPA-BPA
  • HY-W1130442
    DMA4-H228

    		Liposome Inflammation/Immunology Cancer
    DMA4-H228 is a highly spleen-targeted, ionizable cationic liposome. DMA4-H228 is used to prepare lipid nanoparticles (LNPs) loaded with mRNA for the delivery of mRNA in vivo .
    DMA4-H228
  • HY-P992060
    Anti-Mouse CD20 Antibody (18B12)

    		CD20 NF-κB Inflammation/Immunology Cancer
    Anti-Mouse CD20 Antibody (18B12) is a B cell depleting agent that targets mouse CD20. Anti-Mouse CD20 Antibody (18B12) not only inhibits the growth of mesothelioma, lung cancer and thymoma, but also significantly enhances the efficacy of adenoviral tumor antigen vaccines and induces tumor regression by increasing the number of tumor-specific CD8 + T cells. Anti-Mouse CD20 Antibody (18B12) reduces B cell infiltration into the central nervous system of mice with experimental autoimmune encephalomyelitis, and delays motor dysfunction and neuronal death after spinal cord injury by alleviating inflammatory responses and tissue damage. Anti-Mouse CD20 Antibody (18B12) is widely applicable to research in fields related to mesothelioma, lung cancer, thymoma, experimental autoimmune encephalomyelitis and spinal cord injury .
    Anti-Mouse CD20 Antibody (18B12)
  • HY-104004R
    Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH (Standard)

    Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH (Standard); Fmoc-Ser[GalNAc(Ac)3-α-D]-OH (Standard); Fmoc-Ser(Ac3AcNH-α-Gal)-OH (Standard)

    		 Amino Acid Derivatives Reference Standards Drug Intermediate Cancer
    Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH (Standard) is the analytical standard of Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH (HY-104004). This product is intended for research and analytical applications. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH (Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH) is a protected glycosylated amino acid and Tn antigen. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH serves as a building block in the solid-phase synthesis of Tn-based cancer vaccine constructs. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH supports solid-phase peptide synthesis .
    Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: